Across the arc of medical history, treatments for women's health have often arrived before the science fully caught up — or lagged long after the need became clear. The FDA's decision to convene a public meeting on testosterone prescriptions for menopausal women places this moment somewhere in between: a therapy quietly spreading through clinical practice, contested by researchers, and blocked at the pharmacy counter, now drawing the attention of federal regulators who must decide whether to guide it, study it, or restrain it. The meeting is less a resolution than a reckoning — an acknowledgme